Iranian Scientists Make Nano-Carriers for Anti-Rheumatism Drugs to Reduce Side Effects
“This project was implemented jointly with Royan Research Institute, during which studies were carried out in the field of anti-inflammatory drugs due to their side effects in patients,” said Parastou Keshti Ara, one of the researchers,
“In recent years, in order to reduce the problems of different treatment methods, new drug delivery systems have been invented, among them the use of nanoparticles containing organic and inorganic compounds as drug carriers have been given more attention,” she added.
“In this research, efforts were made to develop a drug delivery system based on natural compounds, like natural gums, green tea extract, and the 10-hydroxydecanoic acid compound found in bee royal jelly with anti-rheumatic properties,” Keshti Ara said.
She elaborated on the objectives of the project, saying that synthesis and identification of a new type of core-shell nanoparticles based on natural gums and polyphenol-gold network, evaluation of anti-inflammatory properties of nanoparticles on rheumatoid arthritis model cells, evaluation of biocompatibility of nanoparticles and determination of release mechanism of the medicine were among the goals of this plan.
“This research is in the stage of animal testing,” Keshti Ara said.
In a relevant development in September, an Iranian nanotechnology company also managed to produce and export special drugs with controlled release system.
“We have designed and produced targeted nanoparticles containing anticancer drugs and microparticles with controlled release system,” said Navid Nateqian, the co-founder and a member of the board of directors of Nano Darou Pajouhan Pardis company.
"The first product that we have made is Paclitaxel Albumin Nanoparticles (Pacli-Nab) used for the treatment of cancerous tissues,” he added.
Nateqian noted that the knowledge-based product was so much successful in the market that “it was also welcomed internationally and we were able to start exporting our product from the very first year”.
4155/v
